The United Kingdom is witnessing a growing surge in interest surrounding entheogenic substances. Beyond the common use of psilocybin and LSD, investigators and explorers are increasingly focused on less-charted areas, particularly the copyright compound and the relatively new cannabinoid, CBG. The evolving scene encompasses clinical trials into psy